Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks
- 258 Downloads
In order to examine the endogenous antioxidants values in the earliest phase of demyelination, we have determined bilirubin and uric acid (UA) serum values in the patients with clinically isolated syndrome (CIS) and relapsing remitting multiple sclerosis (RRMS), regarding their clinical disability, measured by Extended Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), disease duration, gender and other parameters. The bilirubin and UA levels were lower in CIS and RRMS patients than in control group, whether male or female (p < 0.05). The bilirubin and UA levels were decreased in RRMS compared to CIS patients (p < 0.05). Regarding EDSS, MRI and disease duration, obtained values of bilirubin and UA were higher in both study groups in patients with lower EDSS, lower MRI lesion number and shorter disease duration (p < 0.05). The greatest significance in decreased bilirubin and UA levels was observed in female compared to male patients, in both study groups (p < 0.05). The results suggest negative linear correlation between bilirubin and UA levels and disease duration, EDSS and MRI in CIS (p < 0.01), with the same correlation between bilirubin and UA levels and disease duration in RRMS patients (p < 0.01). There was also significant correlation between bilirubin level and MRI findings and UA levels and EDSS in RRMS patients (p < 0.01). The obtained results point to the importance of endogenous antioxidants in the outbreak and course of neuroinflammation. This could be favorable for the new pathogenetically conditioned neuroinflammatory therapy concepts which do not initially rely only on immunomodulatory, but also on the antioxidative effects.
KeywordsBilirubin Uric acid Clinically isolated syndrome Relapsing remitting multiple sclerosis
This work was supported by the grant from the scientific project number 41018 financed by the Ministry of Education and Science, Republic of Serbia. No conflict of interest exists for any of the authors listed in the article.
- Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D’Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006PubMedCrossRefGoogle Scholar
- Gonsette RE, Sindic C, Dhooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D, ASIIMS Study Group (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462PubMedCrossRefGoogle Scholar
- Ljubisavljevic S, Stojanovic I, Pavlovic R, Stojnev S, Stevanovic I, Sokolovic D, Pavlovic D (2012) The reduced glutathione and S nitrosothiols levels in acute phase of experimental demyelination—pathophysiological approach and possible clinical relevancy. Neuroscience 219:175–182PubMedCrossRefGoogle Scholar
- Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D (2013) The patients with clinically isolated syndrome and relapsing remitting multiples sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. Neurochem Int 62(7):988–997Google Scholar
- Oliveira SR, Kallaur AP, Simao ANC, Morimoto HK, Lopes J, Panis C, Petenucci DL, Silva E, Cecchini R, Kaimen-Maciel DR, Reiche EMV (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321(1–2):49–53PubMedCrossRefGoogle Scholar
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302PubMedCrossRefGoogle Scholar
- Usha SA, Vickneshwaran V, Sanat KS, Thiagaragan G (2011) Bilirubin and uric acid in traumatic brain injury. J Global Pharma Technol 3(11):20–24Google Scholar